Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TaiGen On-Track for 2014 China Approval of Novel Antibiotic

publication date: May 1, 2014
TaiGen Biotech of Taiwan said that the CFDA review of Taigexyn®, a novel antibiotic for community-acquired pneumonia, is proceeding smoothly. The company is discussing price with China authorities, according to Ming-chu Hsu, CEO and chairman of TaiGen. Two years ago, TaiGen out-licensed China rights for Taigexyn to Zhejiang Medicine. TaiGen anticipates the antibiotic will generate $1.6 million of revenues in China, once it receives final marketing approval later this year. More details....

Stock Symbol: (TWO: 4157)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here